Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis

[1]  C. Beisswenger,et al.  Probenecid-treatment reduces demyelination induced by cuprizone feeding , 2017, Journal of Chemical Neuroanatomy.

[2]  Michael Mousseau,et al.  Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents , 2017, Nature Medicine.

[3]  C. Maack,et al.  Brain damage resulting from postnatal hypoxic-ischemic brain injury is reduced in C57BL/6J mice as compared to C57BL/6N mice , 2016, Brain Research.

[4]  X. Xiong,et al.  Probenecid protects against oxygen–glucose deprivation injury in primary astrocytes by regulating inflammasome activity , 2016, Brain Research.

[5]  E. Scemes,et al.  Pannexin1 Channels Are Required for Chemokine-Mediated Migration of CD4+ T Lymphocytes: Role in Inflammation and Experimental Autoimmune Encephalomyelitis , 2016, The Journal of Immunology.

[6]  C. Meier,et al.  Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis , 2016, Inflammation.

[7]  B. Luo,et al.  Probenecid protects against cerebral ischemia/reperfusion injury by inhibiting lysosomal and inflammatory damage in rats , 2015, Neuroscience.

[8]  K. Stokes,et al.  Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation , 2015, Nature Communications.

[9]  D. Volmer,et al.  Differential distribution of probenecid as detected by on-tissue mass spectrometry , 2015, Cell and Tissue Research.

[10]  D. Volmer,et al.  Differential distribution of probenecid as detected by on-tissue mass spectrometry , 2015, Cell and Tissue Research.

[11]  K. Schroder,et al.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases , 2015, Nature Medicine.

[12]  N. Leitinger,et al.  The role of pannexin1 in the induction and resolution of inflammation , 2014, FEBS letters.

[13]  I. Jalilian,et al.  Probenecid Blocks Human P2X7 Receptor-Induced Dye Uptake via a Pannexin-1 Independent Mechanism , 2014, PloS one.

[14]  Sunhee C. Lee,et al.  Contribution of Pannexin1 to Experimental Autoimmune Encephalomyelitis , 2013, PloS one.

[15]  Young-Joo Lee,et al.  Low‐dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion , 2013, Journal of applied toxicology : JAT.

[16]  D. Yellon,et al.  Novel treatment strategies , 2012 .

[17]  Frauke Zipp,et al.  Neurodegeneration in multiple sclerosis: novel treatment strategies , 2012, Expert review of neurotherapeutics.

[18]  David Baker,et al.  In vitro and in vivo models of multiple sclerosis. , 2012, CNS & neurological disorders drug targets.

[19]  Donna Graves,et al.  Current and emerging therapies in multiple sclerosis: a systematic review , 2012, Therapeutic advances in neurological disorders.

[20]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[21]  Jeffrey A. Cohen,et al.  Multiple sclerosis: new insights in pathogenesis and novel therapeutics. , 2012, Annual review of medicine.

[22]  L. Hua,et al.  The Gap-junction inhibitor Carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells , 2011, Journal of Neuroimmunology.

[23]  Michael R. Elliott,et al.  Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis , 2010, Nature.

[24]  J. P. de Rivero Vaccari,et al.  The Pannexin 1 Channel Activates the Inflammasome in Neurons and Astrocytes* , 2009, The Journal of Biological Chemistry.

[25]  A. Suzumura,et al.  Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. , 2009, The Tohoku journal of experimental medicine.

[26]  J. Buer,et al.  Purinergic Control of T Cell Activation by ATP Released Through Pannexin-1 Hemichannels , 2008, Science Signaling.

[27]  G. Dahl,et al.  Probenecid, a gout remedy, inhibits pannexin 1 channels. , 2008, American journal of physiology. Cell physiology.

[28]  Amaia M. Arranz,et al.  P2X7 Receptor Blockade Prevents ATP Excitotoxicity in Oligodendrocytes and Ameliorates Experimental Autoimmune Encephalomyelitis , 2007, The Journal of Neuroscience.

[29]  W. Gan,et al.  ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.

[30]  G. Dahl,et al.  Pannexin membrane channels are mechanosensitive conduits for ATP , 2004, FEBS letters.

[31]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[32]  Amaia M. Arranz,et al.  P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.